Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 19/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 2/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 1/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cdp840 SCHEMBL29412448 | 1.00 | PDE4A (1.00) | PDE4APDE4DPDE4BPDE4C | |
| Cdp840 SCHEMBL1389110 | 1.00 | PDE4A (1.00) | PDE4APDE4DPDE4BPDE4C | |
| Cdp840 SCHEMBL29351573 | 1.00 | PDE4A (1.00) | PDE4APDE4DPDE4BPDE4C | |
| Cdp840 SCHEMBL153739 | 1.00 | PDE4A (1.00) | PDE4APDE4DPDE4BPDE4C | |
| Cdp840 SCHEMBL15264054 | 0.99 | PDE4D (1.00) | PDE4APDE4DPDE4BPDE4C | |
| Cdp840 SCHEMBL16654879 | 0.99 | PDE4D (1.00) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL6251077 | 0.96 | PDE4A (0.92) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL1387380 | 0.95 | PDE4A (1.00) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL1387378 | 0.95 | PDE4A (1.00) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL1387472 | 0.95 | PDE4A (1.00) | PDE4APDE4DPDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 895 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11903992-B2 | Composition comprising lidocaine, l-carnosine and dexpanthenol | CELLIX BIO PRIVATE LIMITED (IN) | 2024-02-20 | — | — | US | claimed |
| EP-3498297-B1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | STALICLA S A (CH) | 2023-06-21 | — | — | EP | claimed |
| WO-2022190030-A1 | A TOPICAL FORMULATION FOR THE TREATMENT OF SKIN DISEASES | AVACA PHARMA PRIVATE LIMITED (IN) | 2022-09-15 | — | — | WO | claimed |
| US-11439627-B2 | Pharmaceutical composition for the treatment of autism | Stalicla S.A. (CH) | 2022-09-13 | — | — | US | claimed |
| CN-114989054-A | Simple synthesis method of chiral CDP-840 and analogues thereof | 泽升科技(广州)有限公司 | 2022-09-02 | — | — | CN | claimed |
| US-20220233629-A1 | COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-28 | — | — | US | claimed |
| WO-2022157587-A1 | A COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-28 | — | — | WO | claimed |
| US-20220184052-A1 | COMPOSITION COMPRISING FEXOFENADINE | CELLIX BIO PRIVATE LIMITED (IN) | 2022-06-16 | — | — | US | claimed |
| EP-2828242-B1 | NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYLATE AS AGONIST OF THE ß2 ADRENERGIC RECEPTOR. | ALMIRALL SA (ES) | 2017-10-04 | — | — | EP | claimed |
| US-20170049756-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS | GRAS ESCARDO JORDI (ES) | 2017-02-23 | — | — | US | claimed |
| US-6953774-B2 | Methods of inducing ovulation | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2005-10-11 | — | — | US | claimed |
| US-20050148501-A1 | Methods of inducing ovulation using a non-polypeptide camp level modulator | MERCK SERONO SA (CH) | 2005-07-07 | — | — | US | claimed |
| US-20020103106-A1 | Methods of inducing ovulation | MERCK SERONO SA (CH) | 2002-08-01 | — | — | US | claimed |
| WO-2001011933-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING A 7-(2-AMINOETHYL)-BENZOTHIAZOLONE AND A PDE4 INHIBITOR | ASTRAZENECA UK LIMITED (GB) | 2001-02-22 | — | — | WO | claimed |
| JP-H09510691-A | — | — | 1997-10-28 | — | — | JP | claimed |
| US-5622977-A | ANTIINFLAMMATORY AGENT, ANTIALLERGENS | CELLTECH THERAPEUTICS LIMITED (GB) | 1997-04-22 | — | — | US | claimed |
| US-5608070-A | ENZYME INHIBITOR; ANTIINFLAMMATORY, BRONCHODILATOR AGENTS | CELLTECH THERAPEUTICS LIMITED (GB) | 1997-03-04 | — | — | US | claimed |
| EP-0736010-A1 | AN ENANTIOSELECTIVE PROCESS FOR THE PREPARATION OF CHIRAL TRIARYL DERIVATIVES AND CHIRAL INTERMEDIATES FOR USE THEREIN | CELLTECH THERAPEUTICS LIMITED (GB) | 1996-10-09 | — | — | EP | claimed |
| WO-1995035282-A1 | (R)-4-(2-(3-CYCLOPENTYLOXY-4-METHOXYPHENYL)-2-PHENYLETHYL) PYRIDINE HYDROGEN SULPHATE SALT AS PDE TYPE IV INHIBITOR | CELLTECH THERAPEUTICS LIMITED (GB) | 1995-12-28 | — | — | WO | claimed |
| WO-1995017386-A1 | AN ENANTIOSELECTIVE PROCESS FOR THE PREPARATION OF CHIRAL TRIARYL DERIVATIVES AND CHIRAL INTERMEDIATES FOR USE THEREIN | CELLTECH THERAPEUTICS LIMITED (GB) | 1995-06-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170049756-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS | CHRM3, PDE4A, CHRM4 | PDE4A 2/4885PDE4D 11/4885PDE4B 5/4885 |
| US-20050148501-A1 | Methods of inducing ovulation using a non-polypeptide camp level modulator | PDE4A, PDE4B, PDE4C | PDE4A 1/4885PDE4D 8/4885PDE4B 2/4885 |
| US-11903992-B2 | Composition comprising lidocaine, l-carnosine and dexpanthenol | VNN1, LPL, HMGB1 | PDE4A 1073/4885PDE4D 1677/4885PDE4B 1894/4885 |
| US-20020103106-A1 | Methods of inducing ovulation | PDE4A, PDE4B, PDE4C | PDE4A 1/4885PDE4D 8/4885PDE4B 2/4885 |
| US-20220233629-A1 | COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | VNN1, LPL, HMGB1 | PDE4A 1073/4885PDE4D 1677/4885PDE4B 1894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.